The tissue-specific elongation factor eEF1A2 might be an oncoprotein involved in breast cancer. Research published in the open access journal BMC Cancer shows that eEF1A2, which is usually present only in muscle cells and neurons, is abnormally expressed in two thirds of breast tumours. This means it could be used as a new diagnostic marker and, once its role as been identified, as a therapeutic target for the treatment of breast tumours.
Catherine Abbott, Victoria Tomlinson and colleagues, from the University of Edinburgh in the UK, studied the expression of eEF1A2 in breast tumour cells both at the RNA and at the protein level. The results from both analyses show that eEF1A2 is moderately to highly expressed in two-thirds of malignant tumour cells, whereas the protein is only barely expressed in normal breast cells; the expression of eEF1A2 is up to 30-fold higher in tumour cells than in normal cells. Over-expression is considerably more significant in tumour cells bearing the estrogen receptor (ER) than in ER-negative tumour cells: 18% of ER-negative tumours showed slight expression of eEF1A2, whereas 63% of ER-positive tumours showed significant expression of the protein.
Recent studies had shown that eEF1A2 is over-expressed in ovarian cancer cells, but the protein had not been shown to be expressed in breast cancer cells. More research is needed to identify its exact role in the development of breast tumours. "The oncogenicity of eEF1A2 may be related to its role in protein synthesis or to its potential non-canonical functions in cytoskeletal remodelling or apoptosis", write the authors.
Juliette Savin | EurekAlert!
A novel socio-ecological approach helps identifying suitable wolf habitats
17.02.2017 | Universität Zürich
New, ultra-flexible probes form reliable, scar-free integration with the brain
16.02.2017 | University of Texas at Austin
In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".
Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
20.02.2017 | Materials Sciences
20.02.2017 | Health and Medicine
20.02.2017 | Health and Medicine